aTyr Pharma, Inc.ATYRNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+61.5%
5Y CAGR+69.4%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+61.5%/yr
vs -4.7%/yr prior
5Y CAGR
+69.4%/yr
Recent deceleration
Acceleration
+66.1pp
Accelerating
Percentile
P95
Near historical high
vs 5Y Ago
14x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 40.39% |
| Q3 2025 | -47.54% |
| Q2 2025 | 9.84% |
| Q1 2025 | -17.20% |
| Q4 2024 | 0.12% |
| Q3 2024 | 35.61% |
| Q2 2024 | 8.66% |
| Q1 2024 | -102.16% |
| Q4 2023 | -9.52% |
| Q3 2023 | 29.77% |
| Q2 2023 | -684.59% |
| Q1 2023 | 84.02% |
| Q4 2022 | 9.59% |
| Q3 2022 | -38.57% |
| Q2 2022 | 9.76% |
| Q1 2022 | -25.39% |
| Q4 2021 | 29.72% |
| Q3 2021 | -48.06% |
| Q2 2021 | -33.26% |
| Q1 2021 | -8.10% |
| Q4 2020 | 2.89% |
| Q3 2020 | 13.31% |
| Q2 2020 | -439.43% |
| Q1 2020 | 138.17% |
| Q4 2019 | -15.79% |
| Q3 2019 | 11.20% |
| Q2 2019 | 20.09% |
| Q1 2019 | -24.44% |
| Q4 2018 | 25.37% |
| Q3 2018 | 29.68% |
| Q2 2018 | 16.59% |
| Q1 2018 | -5.82% |
| Q4 2017 | -12.12% |
| Q3 2017 | 4.01% |
| Q2 2017 | 31.27% |
| Q1 2017 | -20.52% |
| Q4 2016 | 20.41% |
| Q3 2016 | -4.14% |
| Q2 2016 | -10.61% |
| Q1 2016 | -28.64% |